Back to Search
Start Over
Successful management of persistent COVID-19 using combination antiviral therapy (nirmatrelvir/ritonavir and remdesivir) and intravenous immunoglobulin transfusion in an immunocompromised host who had received CD20 depleting therapy for follicular lymphoma
- Source :
-
Journal of Infection & Chemotherapy (Elsevier Inc.) . Aug2024, Vol. 30 Issue 8, p793-795. 3p. - Publication Year :
- 2024
-
Abstract
- The management of persistent symptomatic coronavirus disease 2019 (COVID-19) infections in immunocompromised patients remains unclear. Here, we present the first case of successful antiviral therapy (nirmatrelvir/ritonavir and remdesivir) in combination with intravenous immunoglobulin (IVIg) in a patient who had received CD20 depleting therapy for follicular lymphoma and experienced recurrent COVID-19 relapses. After the patient received IVIg treatment, the viral load decreased without recurrence. Subsequently, it was found that the anti-spike antibody titer in the administered immunoglobulin was high at 9528.0 binding antibody units/mL. Our case highlights the potential of combination therapy with selective IVIg and antiviral drugs for relapsed immunocompromised COVID-19 patients who have received CD20 depleting therapy. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 1341321X
- Volume :
- 30
- Issue :
- 8
- Database :
- Academic Search Index
- Journal :
- Journal of Infection & Chemotherapy (Elsevier Inc.)
- Publication Type :
- Academic Journal
- Accession number :
- 177870067
- Full Text :
- https://doi.org/10.1016/j.jiac.2024.01.008